The aim of the current studies was to determine the effects of i) HGF neutralizing antibody AMG102, ii) a small molecule inhibitor for c-MET (Compound-A) and iii) the chemotherapeutic agent gemcitabine, alone or in dual and triple combinations on PC progression, using both in vivo and in vitro approaches. The gene discussed is HGF; the disease is pachyonychia congenita.